-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inovio announced the positive results of the first phase III clinical trial of VGX-3100 for cervical precancerous lesions.
This is the fastest DNA therapy clinical trial in the world.
This project is jointly developed by INOVIO and China's innovative oncology pharmaceutical company Dongfanglue.
Infection prevention
HPV stands for Human Papillomavirus, and it is one of the most common viruses that cause infectious diseases.
INOVIO announcements, the REVEAL the phase III trial 1 (pivotal Phase III trial) and REVEAL2 (phase III confirmatory test) in progress, is intended to evaluate and verify the safety VGX-3100, tolerability, immune immunogenic And effectiveness.
immunity
Dr.
Dr.
Dr.
Patients with vulvar cancer and anal cancer will also benefit
Compared with the well-known cervical precancerous lesions, anal precancerous lesions and vulvar precancerous lesions are two other diseases caused by HPV infection, and they are more difficult to treat.
INOVIO announced in early January this year: For the precancerous lesions of the vulva caused by HPV infection, the Phase II clinical trial showed good clinical effectiveness, safety and tolerability.
VGX-3100, as a key R&D project of Oriental Strategy and INOVIO in the field of DNA immunotherapy, once approved, it will be the first in the world to be developed for the treatment of HPV-related precancerous lesions (cervical precancerous lesions, anal precancerous lesions, vulvar precancerous lesions).
Develop biomarkers to improve effectiveness
Dr.
diagnosis
INOVIO announced in February this year that it will continue to cooperate with QIAGEN to develop an in vitro diagnostic product based on RNA sequencing technology in order to more effectively identify the patient population that responds to VGX-3100.
INOVIO stated that it will continue to follow up on REVEAL1 subjects for safety and durable response rates for 18 months after the last dose.
Dongfang Lue focuses on the clinical development and commercialization of innovative oncology drugs, and provides solutions to meet clinical needs.
About VGX-3100
VGX-3100 is the world's first therapeutic drug for HPV 16/18 infection-related precancerous lesions.
Leave a message here
